PRISMA flow diagram.

<p>PRISMA flow diagram.</p

LPS-stimulated production of TNFα (panel A) and IL-6 from whole blood from healthy control subjects (n = 11, black line) and patients with CHF (n = 42, gray line).

<p>* <i>vs.</i> unstimulated control (0 ng/mL LPS); § <i>vs.</i> 0.1 ng/mL LPS; † <i>vs.</i> 1 ng/mL LPS; # <i>vs.</i> 10 ng/mL LPS. One symbol denotes p<0.05, two symbols p<0.01, three symbols p<0.001, four symbols p<0.0001.</p

Distribution of leukocytes (panel A) and their subsets (panels B and C) in healthy control subjects (n = 20) and patients with CHF (n = 75).

<p>Distribution of leukocytes (panel A) and their subsets (panels B and C) in healthy control subjects (n = 20) and patients with CHF (n = 75).</p

Baseline data for control subjects and patients with CHF.

<p>Baseline data for control subjects and patients with CHF.</p

Distribution of lymphocyte subsets in healthy control subjects (n = 20) and patients with CHF (n = 75).

<p>Distribution of lymphocyte subsets in healthy control subjects (n = 20) and patients with CHF (n = 75).</p

Baseline marker of immune activation and cytokines.

<p>Baseline marker of immune activation and cytokines.</p

Table Regression.

<p>NS = non-significant with p>0.2.</p

Effect of β-blockers.

†<p>p<0.05 vs. control; †† p<0.01 vs. control; ††† p<0.001 vs. control; †††† p<0.0001 vs. control * p<0.05 vs. patients on a beta-blocker; ** p<0.01 vs. patients on a beta-blocker; *** p<0.001 vs. patients on a beta-blocker; **** p<0.0001 vs. patients on a beta-blocker. # p-values were calculated using the analysis of variance (ANOVA) method of testing.</p

Additional file 1 of The prevalence and impact of sarcopenia in older cardiac patients undergoing inpatient cardiac rehabilitation – results from a prospective, observational cohort pre-study

Additional file 1. Gender-specific analysis of the assessment result

Medians and interquartile range of plasma CT-proET-1 in 491 patients with CHF according to NYHA class.

<p>Medians and interquartile range of plasma CT-proET-1 in 491 patients with CHF according to NYHA class.</p